Teva Legal Challenge Against "Authorized" Generics Rejected By D.C. Court
This article was originally published in The Pink Sheet Daily
Executive Summary
Any reduction in the economic value of an ANDA first-filer's product during the 180-day exclusivity period "does not rise to the level of absurdity" requiring the court to look beyond the "plain language" of the FD&C Act, D.C. Judge Walton rules. Teva is appealing the decision.